As of 2026-03-26, the EV/EBITDA ratio of Harvard Bioscience Inc (HBIO) is 7.28. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HBIO's latest enterprise value is 51.20 mil USD. HBIO's TTM EBITDA according to its financial statements is 7.03 mil USD. Dividing these 2 quantities gives us the above HBIO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 17.3x | 13.5x |
| Forward P/E multiples | 20.1x - 26.9x | 23.2x |
| Fair Price | 13.33 - 34.72 | 21.77 |
| Upside | 159.8% - 576.8% | 324.4% |
| Date | EV/EBITDA |
| 2026-03-25 | 7.28 |
| 2026-03-24 | 7.28 |
| 2026-03-23 | 7.42 |
| 2026-03-20 | 7.37 |
| 2026-03-19 | 7.59 |
| 2026-03-18 | 7.11 |
| 2026-03-17 | 7.11 |
| 2026-03-16 | 7.20 |
| 2026-03-13 | 7.02 |
| 2026-03-12 | 7.15 |
| 2026-03-11 | 7.24 |
| 2026-03-10 | 7.39 |
| 2026-03-09 | 7.10 |
| 2026-03-06 | 7.53 |
| 2026-03-05 | 7.67 |
| 2026-03-04 | 7.68 |
| 2026-03-03 | 7.63 |
| 2026-03-02 | 7.80 |
| 2026-02-27 | 7.95 |
| 2026-02-26 | 7.86 |
| 2026-02-25 | 7.88 |
| 2026-02-24 | 7.73 |
| 2026-02-23 | 7.64 |
| 2026-02-20 | 7.75 |
| 2026-02-19 | 7.77 |
| 2026-02-18 | 7.81 |
| 2026-02-17 | 7.83 |
| 2026-02-13 | 7.56 |
| 2026-02-12 | 7.59 |
| 2026-02-11 | 7.49 |
| 2026-02-10 | 7.86 |
| 2026-02-09 | 7.39 |
| 2026-02-06 | 7.16 |
| 2026-02-05 | 7.01 |
| 2026-02-04 | 7.26 |
| 2026-02-03 | 7.20 |
| 2026-02-02 | 7.21 |
| 2026-01-30 | 7.20 |
| 2026-01-29 | 7.44 |
| 2026-01-28 | 7.68 |
| 2026-01-27 | 7.80 |
| 2026-01-26 | 7.69 |
| 2026-01-23 | 7.81 |
| 2026-01-22 | 7.99 |
| 2026-01-21 | 7.81 |
| 2026-01-20 | 7.74 |
| 2026-01-16 | 7.77 |
| 2026-01-15 | 7.72 |
| 2026-01-14 | 7.63 |
| 2026-01-13 | 7.80 |